Clearside Biomedical (CLSD) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

CLSD Clearside Biomedical

Watchlist

1.080
0.0000.00%

Close Nov 26 16:00 ET

1.099
+0.019+1.74%

Post 16:19 ET

81.91MMarket Cap-2400P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Clearside Biomedical Is Maintained at Buy by Chardan Capital
Dow JonesNov 15 17:52 ET · Ratings
Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations
Yahoo FinanceNov 15 06:43 ET
JonesTrading Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsNov 13 09:33 ET · Ratings
Promising Outlook for Clearside Biomedical: Buy Rating Backed by Strong Phase 2b ODYSSEY Trial Data and Robust Cash Position
TipRanksNov 13 08:45 ET · Ratings
Oppenheimer Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5
Moomoo NewsNov 13 08:36 ET · Ratings
Needham Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsNov 13 07:35 ET · Ratings

Comments

Jaguar8

Nov 25 06:09

NEWS

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
Clearside Biomedical (NASDAQ: CLSD) showcased its suprachoroidal delivery technology and pipeline programs at multiple medical meetings across Asia, Europe, and the United States. The company made a significant impact at the 17th Asia-Pacific Vitreo-Retina Society Congress in Singapore with presentations on ODYSSEY topline resul...

Jaguar8

Nov 7 08:19

NEWS

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
Clearside Biomedical (CLSD) announced that its Asia-Pacific partner, Arctic Vision, has signed a commercial collaboration agreement with Santen Pharmaceutical for ARVN001 (branded as XIPERE® in the US) for treating uveitic macular edema in China. ...

Jaguar8

Oct 22 06:50

NEWS

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
Clearside Biomedical (Nasdaq: CLSD) presented positive data from its ODYSSEY Phase 2b trial for CLS-AX in wet AMD at the 2024 AAO Annual Meeting. The trial demonstrated extended duration and stable vision, with an 84% reduction in injection frequency after the initial dose. Approximately 90% o...